Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts

REFERENCES

• Patick AK, Mo H, Markowitz M, et al. Antiviral and resis-tance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996;40(2):292–297.
   PubMed Web of Science ®Google Scholar
• Patick AK, Duran M, Cao Y, et al. Genotypic and pheno-typic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 1998 ; 42 (10):2637–2644.
   PubMed Web of Science ®Google Scholar
• Patick AK, Jackson RL, Chang Y, et al. Evaluation of D3ON and L9OM resistance profiles in patients treated with nelfinavir alone or in combination therapy [abstract]. Antivi-ral Ther. 2000;5\(suppl 3):35.
   Google Scholar
• Martinez-Picado J, Severe AV, Sutton L, D'Aquila RT. Rep-licative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73(5):3744–3752.
   PubMed Web of Science ®Google Scholar
• Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibi-tors. AIDS. 200115(5):609–615.
   Web of Science ®Google Scholar
• Kantor R, Zolopa AR, lsraelski D, et al. Evolution of IAS-USA primary protease resistance mutations during pro-tease inhibitor salvage therapy [abstract]. Antiviral Ther. 2001;6\(suppl 1):80.
   Google Scholar
• Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regiman in patients who had previously failed nelfinavir. AIDS. 1999;13(2):F23–28.
   PubMed Web of Science ®Google Scholar
• Zolopa A, Tebas P, Gallant J, et al. The efficacy of ritonavir (RTV)/saquinavir (SQV) antiretroviral therapy (ART) in pa-tients who failed nelfinavir (NFV): a multi-center clinical cohort study. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Che-motherapy; September 26–29,1999; San Francisco, Cali-fornia. Abstract 2065.
   Google Scholar
• Winters MA, Schapiro JM, Lawrence J, Merigan TC. Hu-man immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease in-hibitors after long-term saquinavir treatment. J ViroL 1998;72(6):5503–5306.
   Web of Science ®Google Scholar
• Dronda F, Casado JL, Moreno S, et al. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retro viruses. 200117(3):211–215.
   Google Scholar
• Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure [abstract]. Antivi-ral Ther. 1999;4\(suppl 1):44.
   Google Scholar
• Sugiura W, Matsuda Z, Yokomaku Y, et al. Evidence of a mutually exclusive relationship between the HIV-1 pro-tease inhibitor resistance mutations D3ON and L9OM [ab-stract]. Antiviral Ther. 2000;5\(suppl 3):33.
   PubMed Web of Science ®Google Scholar
• Parkin NT, Chappey C, ViroLogic Clinical Reference Labo-ratory. Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV-1 isolates containing mutations at positions 82 or 90: modulatory effects of mutations at positions 46 and 54 [abstract]. Antiviral Ther. 2000;5\(suppl 3):50.
   Google Scholar
• Saah A, Haas DW, Rhodes R, et al. Virologic response to indinavir (IDV), efavirenz (ER)) and adefovir (ADV) among patients failing nelfinavir (NFV). In: Program and abstracts of the XIII International Conference on AIDS; July 9–14, 2000; Durban, South Africa. Abstract WePeB4169.
   Google Scholar
• Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994;169(4):722–729.
   PubMed Web of Science ®Google Scholar
• Richman DD, Haylir D, Corbeil J, et al. Nevirapine resis-tance mutations of human immunodeficiency virus type 1 selected during therapy. J ViroL 1994;68(3):1660–1666.
   PubMed Web of Science ®Google Scholar
• Ait-Khaled M, Rakik A, Griffin P, et al. HIV-1 reverse tran-scriptase (RT) genotypes from patients receiving abacavir/ efavirenz/amprenavir ± other antiretroviral therapy (ART): a 48-week follow-up [abstract]. Antiviral Ther. 2001;6(1):S14–15.
   Google Scholar
• Saag MS, Tebas P, Sension M, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS. 2001;15(15):1971–1978.
   PubMed Web of Science ®Google Scholar
• Agouron Pharmaceuticals Inc. Research report PH-1201-096.1996.
   Google Scholar
• Gartland M. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antiviral Ther. 2001;6(2):127–134.
   PubMed Web of Science ®Google Scholar
• Maguire M, Gartland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naive patients fol-lowing zidovudine/lamivudine/protease inhibitor combina-tion therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS. 2000;14(9):1195–1201.
   PubMed Web of Science ®Google Scholar
• Kempf D, Bernstein B, King M, et al. Comparison of the emergence of genotypic resistance over 60 weeks of therapy with lopinavir/ritonavir (KaletraTM) or nelfinavir plus d4T/3TC. In: Program and abstracts of the First IAS Con-ference on HIV Pathogenesis and Treatment; July 8–11, 2001; Buenos Aires, Argentina. Abstract 129.
   Google Scholar
• Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345(6):398–407.
   PubMed Web of Science ®Google Scholar
• Katzenstein DA, Bosch R, Albrecht M, Shafer R, Winters MA. Protease genotype and virologic failure in nucleoside-experienced subjects treated with two NRTIs, nelfinavir (NFV) and/or efavirenz (ER)) in ACTG 364 [abstract]. Antivi-ral Ther. 2000;5\(suppl 3):80–81.
   Google Scholar
• Yerly S, Rickenbach M, Popescu M, et al. Drug resistance mutations in HIV-1-infected subjects during protease in-hibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Antiviral Ther. 2001;6(3):185–189.
   PubMed Web of Science ®Google Scholar
• Masquelier B, Raffi F, Droz C, et al. Assessment of virologi-cal failures in HIV-1 infected patients initiating a first-line P1-containing regimen (APROCO-ANRS EP11 study) [ab-stract]. Antiviral Ther. 2001 ;6(1):S19–20 .
   Google Scholar
• Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected pa-tients from a trial of induction-maintenance therapy. JAMA. 2000;283(2):205–211.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug sus-ceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283(2):229–234.
   PubMed Web of Science ®Google Scholar
• Gallego O, de Mendoza C, Pérez-Elías MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS. 2001;15(13):1701–1706.
   PubMed Web of Science ®Google Scholar